AzTrials
AzTrials

Intrapartum - Moderate and Severe AnaemiaPhase 3WOMAN-2NCT03475342

World Maternal Antifibrinolytic Trial_2

A Phase 3 study testing Tranexamic Acid in people with Intrapartum - Moderate and Severe Anaemia, run by London School of Hygiene and Tropical Medicine at 41 sites in 4 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, almost all of which occur in low and middle income countries. When given within three hours of birth, tranexamic acid reduces deaths due to bleeding in women with PPH by almost one third. Read more about this study

Who is it for?
Any age, women only
What is being tested?
Tranexamic Acid
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
15,068 participants
Where
41 sitesin 4 countries
Study dates
24 Aug 2019to 29 Oct 2023
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Women with moderate or severe anaemia (haemoglobin level <100 g/L or packed cell volume <30%) after giving birth vaginally where the responsible clinician is substantially uncertain whether to use TXA

Who cannot join

  • Women who are not legally adult (<18 years) and not accompanied by a guardian
  • Women with a known allergy to tranexamic acid or its excipients
  • Women who experience postpartum haemorrhage before the umbilical cord is cut or clamped.

Trial locations and contacts

41 sites in 4 countries.

41 sites in 4 countries

Pakistan25 sites
  • Ayub Teaching Hospital (Unit A)

    Abbottabad

  • Ayub Teaching Hospital (Unit C)

    Abbottabad

  • Ayub Teaching Hospital Unit B

    Abbottabad

  • Bahawalpur Victoria Hospital

    Bahawalpur

  • Aziz Bhatti Teaching Hospital

    Gujrat

  • MCH PIMS

    Islamabad

  • Military Hospital

    Islamabad

  • Civil Hospital

    Karachi

  • Jinnah Postgraduate Medical Centre

    Karachi

  • Koohi Goth Hospital

    Karachi

  • Jinnah Hospital

    Lahore

  • Services Hospital

    Lahore

  • Sir Ganga Ram Hospital Unit 1

    Lahore

  • Sir Ganga Ram Hospital Unit 2

    Lahore

  • Sir Ganga Ram Hospital Unit 3

    Lahore

  • Sir Ganga Ram Hospital Unit 4

    Lahore

  • Chandka SMBBMU Sheikh Zaid Woman Hospital Unit 1

    Larkana

  • Chandka SMBBMU Sheikh Zaid Woman Hospital Units 2 & 3

    Lārkāna

  • Nishtar Hospital Unit 1

    Multan

  • Nishtar Hospital Unit 2

    Multan Khurd

  • Nishtar Hospital Unit 3

    Multan Khurd

  • Bolan Medical Centre

    Quetta

  • Benazir Bhutto Shaheed Hospital

    Rawalpindi

  • Federal Government Polyclinic

    Rawalpindi

  • Holy Family Hospital

    Rawalpindi

Other trials in Pakistan

Tanzania8 sites
  • Mount Meru Regional Referral Hospital

    Arusha

  • Amana Regional Referral Hospital,

    Dar es Salaam

  • Muhimbili National Hospital

    Dar es Salaam

  • Temeke Regional Referral Hospital

    Dar es Salaam

  • Dodoma Regional Referral Hospital

    Dodoma

  • Tumbi Regional Referral Hospital, Kibaha

    Kibaha

  • Mwananyamala Regional Referral Hospital

    Kinondoni

  • Mbeya Zonal Referral Hospital

    Mbeya

Other trials in Tanzania

Nigeria7 sites
  • Mother & Child Hospital

    Akure

  • University of Medical Sciences Teaching Hospital

    Akure

  • Adeoyo Maternity Hospital

    Ibadan

  • Ilorin General Hospital

    Ilorin

  • Muhammad Abdullahi Wase Specialist Hospital

    Kano

  • Ladoke Akintola University of Technology Teaching Hospital

    Ogbomoso

  • State Hospital

    Oyo

Other trials in Nigeria

Zambia1 site
  • Women and Newborn Hospital

    Lusaka

Other trials in Zambia

About this study

Official title: Tranexamic Acid for the Prevention of Postpartum Bleeding in Women With Anaemia: an International, Randomised, Double-blind, Placebo Controlled Trial.

Postpartum haemorrhage (PPH) is responsible for about 100,000 maternal deaths every year, almost all of which occur in low and middle income countries. When given within three hours of birth, tranexamic acid reduces deaths due to bleeding in women with PPH by almost one third. However, for many women, treatment of PPH is too late to prevent death and severe morbidities. Over one-third of pregnant women in the world are anaemic and many are severely anaemic. We now want to do the WOMAN-2 trial to see if giving tranexamic acid can prevent PPH and other severe outcomes in women with moderate and severe anaemia.

Read the detailed description

Anaemia is a cause and consequence of PPH. A cohort study in Assam, India found that women with moderate or severe anaemia had a greatly increased risk of PPH. Women with moderate anaemia had a 50% increased risk, whereas those with severe anaemia had a ten-fold increased risk of PPH. Anaemic women may be more susceptible to uterine atony due to impaired oxygen transport to the uterus. Anaemic women experience worse outcomes after PPH. An international survey of 275,000 women found that severe maternal outcomes after PPH were nearly three times more common in anaemic than in non-anaemic women. Even moderate bleeding can be life threatening in anaemic women. Excessive bleeding after childbirth worsens maternal anaemia, resulting in a vicious circle of bleeding and adverse outcomes. Fatigue due to anaemia severely limits a mothers' wellbeing and her ability to care for her children. Despite efforts to prevent anaemia, many women labour with perilously low haemoglobin levels

Tranexamic acid (TXA) inhibits fibrinolysis by blocking the lysine binding sites on plasminogen. TXA reduces surgical bleeding and death due to bleeding in trauma patients. The WOMAN trial assessed the effects of TXA in 20,060 women with PPH. When given within three hours of birth, TXA reduced death due to bleeding by nearly one-third (RR=0.69, 95% CI 0.52 to 0.91, p=0.008). However, for many women, treatment is too late to prevent death from PPH. Most PPH deaths occur in the first hours after giving birth and women with anaemia are at greatly increased risk. Whilst there have been some trials of TXA for the prevention of PPH, most have serious flaws and none collected data on maternal health and wellbeing. There is currently no reliable evidence about the effectiveness and safety of TXA for preventing PPH.

The WOMAN-2 trial will determine reliably the effects of TXA in anaemic women who give birth vaginally.

We will also conduct a pre-planned cohort analysis of data from the WOMAN-2 trial to assess the effect of pain control and episiotomy on the risk of post-partum haemorrhage. Adrenaline is a potent stimulus for fibrinolysis. Adrenaline causes the release of tissue plasminogen activator (TPA) from the endothelium. In trauma victims, high adrenaline levels are associated with increased fibrinolysis, decreased clot strength and increased deaths due to bleeding. Childbirth is intensely painful and maternal adrenaline levels are two to six times higher during labour. Maternal adrenaline concentrations peak in the second and third stages of labour but then rapidly return to normal after birth. Pain control can reduce the maternal catecholamine response. We hypothesize that painful procedures such as episiotomy will significantly increase the risk of postpartum haemorrhage and that pain control will reduce the risk of PPH.

The exposures of interest are the presence or absence of pain control during labour and delivery and whether episiotomy was conducted prior to birth. Pain control will be categorised as present or absent but the type of pain control administered during labour will also be described and examined. The types of pain control recorded in the study are epidural, opioids, 'other', or a combination of opioids and other pain control. For the multivariable regression analysis, the pain control variable was converted into a binary variable indicating whether a participant received any pain control or not. Episiotomy will be categorised as present or absent according to the CRF. The main outcome variable will be a clinical diagnosis of PPH (binary: yes/no), defined as an estimated blood loss of more than 500 mL or any blood loss sufficient to compromise haemodynamic stability within 24 hours. Potential confounding factors will include maternal age, BMI, anaemia, history of PPH, antepartum hemorrhage, hypertensive disease, multiple gestation, parity, prophylactic uterotonics, duration of labor, induction and augmentation of labor, assisted delivery, gestational age, birth canal trauma, placental abruption, and macrosomia.

We will use multivariable logistic regression to examine the association between pain control and episiotomy and the risk of PPH after adjusting for confounding factors. We will describe our causal assumptions using a directed acyclic graph. We will examine the association between the exposures of interest and PPH with odds ratios and 95% confidence intervals. We will estimate odds ratios and 95% CI for the crude association between the exposures of interest and PPH and after controlling for confounding factors. We will check for collinearity using variance inflation factors. Finally, we will examine whether the effect of pain control and episiotomy on the risk of PPH is modified by tranexamic acid treatment. To do this we will conduct stratified analysis and calculate a p-value for heterogeneity using a likelihood ratio test.

Being tested
Tranexamic Acid, Placebo
Keywords
prevention, postpartum haemorrhage, moderate anaemia, severe anaemia, antifibrinolytic, tranexamic acid, pregnancy, pain, episiotomy
Medical subject headings
Anemia, Postpartum Hemorrhage, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Tranexamic AcidDrug

    Ampoules and packaging for both arms will be identical in appearance.

  • PlaceboOther

    Also called (Sodium Chloride 0.9%)

    Ampoules and packaging for both arms will be identical in appearance.

Study groups in NCT03475342
Study groupRoleWhat they receive
Tranexamic acidActive comparatorOne intravenous injection of tranexamic acid. Total dose 1 gram (10mL)
Receives: Drug: Tranexamic Acid
PlaceboPlacebo comparatorOne Injection of the placebo which is 10 mL Sodium Chloride (0.9%)
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Postpartum Haemorrhage (cause will be described)

    Clinical assessment: This may be an estimated blood loss of more than 500 mL or any blood loss sufficient to compromise haemodynamic stability within 24 hours of delivery. Haemodynamic instability is based on clinical judgement and assessed using clinical signs (low systolic blood pressure, tachycardia, reduced urine output).

    Measured: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier

Secondary outcomes (19)
  1. Postpartum blood loss

    Clinical assessment

    Measured: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier

  2. Haemoglobin

    Haemocue (Point of care test)

    Measured: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier

  3. Haemodynamic instability

    Defined as per protocol

    Measured: 24 hours after administration of trial treatment or discharge from hospital, whichever is earlier

  4. Shock index

    Heart rate/systolic blood pressure

    Measured: 24 hours after administration of trial treatment or discharge from hospital, whichever is earlier

  5. Quality of Life (maternal)

    Defined as per protocol

    Measured: Day 42 or discharge from hospital, whichever is earlier

  6. Expected side effects of trial medication

    nausea, vomiting, diarrhoea

    Measured: Day 42 or discharge from hospital, whichever is earlier

  7. Exercise tolerance

    6 minute walk test

    Measured: Day 42 or discharge from hospital, whichever is earlier

  8. Interventions to control primary postpartum haemorrhage (medical and surgical)

    Any of the following: uterotonics, removal of placenta/placenta fragments, intrauterine balloon tamponade, bimanual uterine compression, external aortic compression, non-pneumatic anti-shock garments, uterine artery embolisation, uterine compression suture, hysterectomy and laparotomy to control bleeding

    Measured: Day 42 or discharge from hospital, whichever is earlier

  9. Receipt of blood product transfusion

    units and type

    Measured: Day 42 or discharge of mother from hospital, whichever is earlier

  10. Vascular occlusive events

    Any of the following:pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, myocardial infarction

    Measured: Day 42 or discharge from hospital, whichever is earlier

  11. Symptoms of anaemia

    measured using Quality of life Questionnaire and walk test

    Measured: Day 42 or discharge of mother from hospital, whichever is earlier

  12. Organ disfunction

    Any of the following: Cardiovascular, Respiratory, Renal, Hepatic, Neurological, Coagulation/ haematologic dysfunction

    Measured: Day 42 or discharge from hospital, whichever is earlier

  13. Sepsis

    diagnosis is based on the presence of both infection and a systemic inflammatory response syndrome (SIRS). SIRS requires two or more of the following: a) temperature <36°C or >38°C (b) heart rate >90 beats/min (c) respiratory rate >20 breaths/min (d) white blood cell count <4x109/L (<4000/mm³) or >12x109/L (>12,000/mm³)

    Measured: Day 42 or discharge from hospital, whichever is earlier

  14. In hospital death

    Cause and time of death will be described

    Measured: Day 42

  15. Length of hospital stay.

    Days

    Measured: Day 42 or discharge from hospital, whichever is earlier

  16. Admission to and time spent in higher level facility

    High Dependency and/or Intensive Care Units

    Measured: Day 42 or discharge from hospital, whichever is earlier

  17. Status of baby/ies

    alive or dead

    Measured: Day 42 or discharge of mother from hospital, whichever is earlier

  18. Thromboembolic events in breastfed babies

    as defined in protocol

    Measured: Day 42 or discharge of mother from hospital, whichever is earlier

  19. Adverse events

    Any untoward medical occurrence (other than expected complications)

    Measured: Day 42

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Mar 2018
  2. Study start24 Aug 2019
  3. Primary completion20 Sep 2023
  4. Study completion29 Oct 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
A randomised, double blind, placebo controlled trial among 15,000 women with moderate or severe anaemia having given birth vaginally.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
15,068 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03475342
Sponsor's protocol ID
WOMAN_2
Other IDs
03475342
Acronym
WOMAN-2
Status last verified
Apr 2023
First submitted
23 Feb 2018
Last updated
10 Jan 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Data will be shared publicly when all planned analyses are completed by the Woman-2 Trial Collaborators. This will be hosted on freebird.lshtm.ac.uk

Publications

  • WOMAN-2 Trial Collaborators. The effect of tranexamic acid on postpartum bleeding in women with moderate and severe anaemia (WOMAN-2): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2024 Oct 26;404(10463):1645-1656. doi: 10.1016/S0140-6736(24)01749-5.

    PubMed 39461792
  • Larson NJ, Mergoum AM, Dries DJ, Cook A, Blondeau B, Rogers FB. THE ROLE OF TRANEXAMIC ACID IN POSTPARTUM HEMORRHAGE: A NARRATIVE REVIEW. Shock. 2024 Nov 1;62(5):620-627. doi: 10.1097/SHK.0000000000002455. Epub 2024 Aug 20.

    PubMed 39162220
  • Collier T, Shakur-Still H, Roberts I, Balogun E, Olayemi O, Bello FA, Chaudhri R, Muganyizi P; WOMAN-2 Trial Collaborators. Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: Statistical analysis plan for the WOMAN-2 trial: an international, randomised, placebo-controlled trial. Gates Open Res. 2023 Aug 3;7:69. doi: 10.12688/gatesopenres.14529.2. eCollection 2023.

    PubMed 37664793
  • Brenner A, Roberts I, Balogun E, Bello FA, Chaudhri R, Fleming C, Javaid K, Kayani A, Lubeya MK, Mansukhani R, Olayemi O, Prowse D, Vwalika B, Shakur-Still H. Postpartum haemorrhage in anaemic women: assessing outcome measures for clinical trials. Trials. 2022 Mar 18;23(1):220. doi: 10.1186/s13063-022-06140-z.

    PubMed 35303924
  • Ker K, Roberts I, Chaudhri R, Fawole B, Beaumont D, Balogun E, Prowse D, Pepple T, Javaid K, Kayani A, Arulkumaran S, Bates I, Shakur-Still H; WOMAN-2 trial collaborators. Tranexamic acid for the prevention of postpartum bleeding in women with anaemia: study protocol for an international, randomised, double-blind, placebo-controlled trial. Trials. 2018 Dec 29;19(1):712. doi: 10.1186/s13063-018-3081-x.

    PubMed 30594227

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Tranexamic Acid in people with Intrapartum - Moderate and Severe Anaemia, run by London School of Hygiene and Tropical Medicine at 41 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 41 sites in Pakistan, Tanzania, Nigeria, Zambia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Postpartum Haemorrhage (cause will be described) (time frame: 24 hours after administration of the trial medication or at discharge from hospital, whichever is earlier). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03475342, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Jan 2024; AzTrials last refreshed its copy on 29 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in